Arcutis Biotherapeutics, Inc. (ARQT) Stock Price & Analysis
Arcutis Biotherapeutics, Inc. (ARQT) rose 1.01% to USD 23.9 as of September 8, 2026 at 06:58 UTC, according to Nexqual real-time market data.
ARQT last closed at USD 23.9; the session ranged USD 23.27–24.02 on volume of 1,631,999 shares. Market capitalization is —, with a 52-week range of USD 16.57–31.77 (NMS). Source: Nexqual, September 8, 2026 at 06:58 UTC.
Key Statistics (as of September 8, 2026 at 06:58 UTC)
| Price | USD 23.9 |
|---|---|
| Change | ▲ 1.01% (up) |
| Previous Close | USD 23.9 |
| Open | USD 23.9 |
| Day Range | USD 23.27 – 24.02 |
| 52-Week Range | USD 16.57 – 31.77 |
| Volume | 1,631,999 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (ARQT)
Nexqual's technical model rates ARQT "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:58 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.68 (neutral) |
| vs SMA50 | Below (USD 26.37) |
| MACD | -0.73 (negative) |
From Arcutis Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026.
- We believe we have built a leading platform for dermatologic product development and commercialization.
- We believe our management team's experience in developing dermatological drugs, including biologics, will enable us to effectively move ARQ-234 through the development process.
Partnerships
- In July 2018, we executed a licensing agreement with AstraZeneca AB (AstraZeneca) for exclusive worldwide rights to roflumilast as a topical product in humans solely for dermatological indications.
- In August 2023, we entered into a strategic collaboration and licensing agreement (the Huadong Agreement) for topical roflumilast in Greater China and Southeast Asia with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Huadong). a wholly owned subsidiary of Huadong Medicine Co., Ltd.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | USD 29.81 | ▼ 2.26% |
| CCCC | C4 Therapeutics, Inc. | USD 3.76 | ▼ 0.79% |
| TVTX | Travere Therapeutics, Inc. | USD 65.28 | ▼ 2.9% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 84.95 | ▲ 0% |
| ALXO | ALX Oncology Holdings Inc. | USD 2.01 | ▼ 3.37% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:58 UTC. This page is informational and not investment advice.